USE OF TISSUE PREPARATION FROM REMOVED TUMORS IN COMPLEX THERAPY OF BITCHES WITH MAMMA TUMORS
Keywords:
tumor, dog, cancer, mammary gland, vaccine, immunotherapy, recurrence.Abstract
Mammary tumors are the most common neoplasms in dogs and are a frequent cause of death in bitches. Until recently, cancer was considered exclusively as a surgical disease, however, frequent failures of surgical treatment of tumors of a certain localization and stages of the blastomonosis process caused the need to search for new methods of therapy. The aim of the study was to scientifically substantiate and develop optimal schemes for the use of a tissue antitumor vaccine for mammary neoplasms in bitches. It was established that mammary tumors in bitches make up more than 50% of all neoplasms in dogs, and the frequency of their malignant manifestation increases with the age of the animals. The clinical features of blastomogenesis at different stages of benign tumors and inflammatory mammary cancer were clarified. The object of the research were bitches with benign mammary tumors (T2, T3), from which two experimental groups were formed. According to the results of the clinical experiment, it was established that the use of an antitumor vaccine accelerated the healing time of the surgical wound by an average of 3.2 days, contributed to the prevention of postoperative complications and recurrence of the blastomonosis process. The proposed complex scheme of surgical-conservative treatment of dogs with mammary tumors increases the body's resistance to the blastomonosis process, stimulates regenerative processes and contributes to a more favorable course of the postoperative period. The data obtained can be used for further study of the nature of neoplasms in dogs, development of new methods of their treatment and prevention.
References
Bray, F., Laversanne, M., Sung, H. et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 74(3):229 63. https://doi.org/10.3322/caac.21834.
Sung, H., Ferlay, J., Siegel, R.L, Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin., 71. 209–249.
Schiffman, J.D., Breen, M. (2015). Comparative oncology: What dogs and other species can teach us about humans with cancer. Philos. Trans. R. Soc. Biol. Sci. 370. 20140231. doi: 10.1098/rstb.2014.0231.
Gardner, H.L., Fenger, J.M., London, C.A. (2016). Dogs as a Model for Cancer. Annu. Rev. Anim. Biosci, 4. 199–222.
Davis, B.W., Ostrander, E.A. (2014). Domestic Dogs and Cancer Research: A Breed-Based Genomics Approach. ILAR J., 55. 59–68.
Sorenmo, K., Worley, D., Zappulli, V. (2020). Tumors of the mammary gland. In: Vail D., Thamm D., Liptack J., editors. Small animal clinical oncology. 6 th ed. St. Louis, MO: Elsevier; 604-25.
Horta, R.S., Figueiredo, M.S., Lavalle, G.E., Costa, M.P., Cunha, R.M., Araujo, R.B. (2015). Surgical stress and postoperative complications related to regional and radical mastectomy in dogs. Acta Vet Scand., 24;57(1):34.
Rueda, Jr., Porto, Cd., Franco, Rp., da Costa, Ib., Bueno, Lmc., Girio, Rjs., … Repetti Csf. (2024). Mammary neoplasms in female dogs: Clinical, diagnostic and therapeutic aspects. Veterinarni Medicina. 69(4), 99-114. DOI: 10.17221/4/2024-VETMED
Zhang, Y., Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol., 17(8):807–21. https://doi.org/10.1038/s41423-020-0488-6.
Zhou, Y., Wei, Y., Tian, X. et al. (2025). Cancer vaccines: current status and future directions. J. Hematol. Oncol. 18,18 https://doi.org/10.1186/s13045-025-01670-w.
Yaddanapudi, K., Mitchell, R. A., Eaton, J. W. (2013). Cancer vaccines. Looking to the future. OncoImmunology, 2(3). https://doi.org/10.4161/onci.23403
Oladejo, M., Paulishak, W., Wood, L. (2023). Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Semin Cancer Biol., 88:81–95. https://doi.org/10.1016/j.semcancer.2022.12.003.
Lin, M.J., Svensson-Arvelund, J., Lubitz. G.S. et al. (2022). Cancer vaccines: the next immunotherapy frontier. Nat. Cancer, 3(8), 911–26. https://doi.org/10.1038/s43018-022-00418-6
Bodnar O.O., Bodnar A.O. (2018). Dosvid likuvannia suk z novoutvorenniamy molochnoi zalozy iz zastosuvanniam tkanynnoho preparatu z vydalenykh pukhlyn. [Experience in treating bitches with mammary gland tumors using tissue preparations from removed tumors]. Modern methods of diagnostics, treatment and prevention in veterinary medicine: theses of the supplementary conference, Lviv, 29-30 Nov. 2018 / Lviv. Nat. Univ. of Vet. Med. and Biotechn. n. after S. Z. Gzhytsky. Lviv. 17-18. [in Ukrainian].
Tosch, C., Bastien, B., Barraud, L., et al. (2017). Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. J. Immunother. Cancer., 5(1), 70. https://doi.org/10.1186/s40425-017-0274-x.
Lasser, S.A., Ozbay Kurt, F.G., Arkhypov, I., Utikal, J., Umansky, V. (2024). Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol., 21(2), 147–64. https://doi.org/10.1038/s41571-023-00846-y.
Vazquez, E., Lipovka, Y., Cervantes-Arias, A., Garibay-Escobar. A., Haby, M.M., Queiroga, F.L., Velazquez, C. (2023). Canine Mammary Cancer: State of the Art and Future Perspectives. Animals., 13, 31-47. https://doi.org/10.3390/ani13193147.
Mysak, A.R., Pritsak, V.V., Ivashkiv, B.B. (2022). Mammary gland neoplasias in bitches (spreading, diagnosis, treatment methods). Topical issues of the development of veterinary medicine and breeding technologies: Scientific monograph. Riga, Latvia: “Baltija Publishing”. 73 - 132. ISBN 978-9934-26-203-6 https://doi.org/10.30525/978-9934-26-258-6-4
Rutteman, G., Withrow, SEGM. (2001). Tumors of the mammary gland. In: Withrow S.J., MacEwen E., editors. Small Animal Clinical Oncology. 3rd ed. Philadelphia, PA: WB Saunders. 455–77.
Cassali, G.D., Jark, P.C., Gamba, C., Damasceno, K.A., Estrela-Lima, A., De Nardi A.B., … Nakagak K.Y.R. (2019). Consensus regarding the diagnosis, prognosis and treatment of canine and feline mammary tumors. Braz. J. Vet. Pathol., 13(3), 555-74.
Sposib imunoterapii pukhlyn: patent 64 928 Ukraina [Method of immunotherapy of tumors: patent 64 928 Ukraine], MPK A 61 R 35/00, A 61 D 99/00u 2011 04468; zaiavl. 12.04.2011; opubl.25.11.2011. Biul. №22. 3 s. [in Ukrainian].
Sposib oderzhannia protypukhlynnoi vaktsyny: patent 64927 Ukraina [Method of obtaining anti-tumor vaccine: patent 64927 Ukraine], MPK A 61 K 35/12, A 61 R 35/00. u 2011 04467; zaiavl. 12.04.2011; opubl. 25.11.2011. Biul. №22. 3 s. [in Ukrainian].
Yaddanapudi, K., Mitchell, R. A., Eaton, J. W. (2013). Cancer vaccines Looking to the future. OncoImmunology, 2(3), https://doi.org/10.4161/onci.23403.
Lohmueller, J., Finn O.J. (2017). Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther., 178, 31–47. 10.1016/j.pharmthera. 2017.03.008.
Gatti-Mays, М. Е., Redman, J. M., Collins J. M., Bilusic, M. (2017). Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Human Vaccines & Immunotherapeutics, 13(11), 25612574https://doi.org/10.1080/21645515.2017.1364322.
Chiang, C.L.L., Coukos, G., Kandalaft, L.E. (2015). Whole tumor antigen vaccines: where are we? Vaccines, 3(2), 344–72.
Oladejo, M., Paulishak, W., Wood, L. (2023). Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Seminars in Cancer Biology, 88,81–95. https://doi.org/10.1016/j.semcancer.2022.12.003.
Lin, M.J., Svensson-Arvelund, J., Lubitz, G.S., et al. (2022). Cancer vaccines: the next immunotherapy frontier. Nat Cancer, 3(8), 911–26. https://doi.org/10.1038/s43018-022-00418-6
Saxena, M., van der Burg, S. H., Melief, C .J. M., Bhardwaj, N. (2021). Therapeutic cancer vaccines. Nat. Rev. Cancer, 21(6), 360–78. https://doi.org/10.1038/s41568-021-00346-0.
Tosch, C., Bastien, B., Barraud, L., et al. (2017). Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. J. Immunother. Cancer, 5(1), 70. https://doi.org/10.1186/s40425-017-0274-x.
Ott, P.A., Hu-Lieskovan, S., Chmielowski, B., et al. (2020). A Phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell., 183(2), 347-362.e24. https://doi.org/10.1016/j.cell.2020.08.053.
Carreno, B.M., Magrini, V., Becker-Hapak, M., et al. (2015). Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 15, 348(6236):803-8. https://doi.org/10.1126/science.aaa3828.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
